-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Thoracic Cancer published the results of a phase II clinical study, mainly to evaluate the efficacy and safety of nab-paclitaxel combined with carboplatin after the progression of standard chemotherapy for small cell lung cancer (SCLC)
.
.
Mainly to evaluate the efficacy and safety of nab-paclitaxel combined with carboplatin after the progression of standard chemotherapy for small cell lung cancer (SCLC)
Enrolled patients received nab-paclitaxel (100 mg/m2, d1, d8, and d15), and carboplatin (AUC=5, d1) every 3 weeks until disease progression or unacceptable toxicity
.
The primary endpoint was objective response rate
Enrolled patients received nab-paclitaxel (100 mg/m2, d1, d8, and d15), and carboplatin (AUC=5, d1) every 3 weeks until disease progression or unacceptable toxicity
A total of 21 patients were included in the study, all of whom were eligible for inclusion in the analysis
.
The median age was 70 years (range: 54 to 85), 18 patients were male (85.
A total of 21 patients were included in the study, all of whom were eligible for inclusion in the analysis
Partial responses were achieved in 4 patients and stable disease in 6 patients, with an overall response rate of 19.
The median progression-free survival was 2.
5 months (95% CI: 1.
5-3.
4 months), and the median survival time was 5.
1 months (95% CI: 2.
1-8.
1 months)
.
5 months (95% CI: 1.
5-3.
4 months), and the median survival time was 5.
1 months (95% CI: 2.
1-8.
1 months)
.
The median progression-free survival was 2.
Eighteen (85.
7%) patients experienced grade 3 or 4 hematological toxicity
.
11 cases (52.
Eighteen (85.
In conclusion, the study showed that the combination of carboplatin + albumin-paclitaxel has certain efficacy in the treatment of recurrent SCLC, although the primary endpoint was not met
.
.
Studies have shown that the combination of carboplatin + albumin-paclitaxel has some efficacy in the treatment of recurrent SCLC, although the primary endpoint was not met
Original source:
Original source:Naoya Ikeda, Ryo Arai, Sayo Soda, et al.
Carboplatin plus nab-paclitaxel for recurrent small cell lung cancer: A phase II study.
Thorac Cancer.
2022;1–7.
DOI: 10.
1111/1759-7714.
14394.
Carboplatin plus nab-paclitaxel for recurrent small cell lung cancer: A phase II study.
Thorac Cancer.
2022;1–7.
DOI: 10.
1111/1759-7714.
14394.
leave a message here